Target intelligence / Profile preview

Fast skeletal muscle myosin (None commonly used; sometimes abbreviated as "fast MyHC" (myosin heavy chain) in literature, but no universal abbreviation.)

Target
None commonly used; sometimes abbreviated as "fast MyHC" (myosin heavy chain) in literature, but no universal abbreviation.
Molecular classification
Motor protein, Enzyme (ATPase activity), Structural protein of the sarcomere, Contractile protein
01

Overview

Fast skeletal muscle myosin refers to a family of motor proteins predominantly expressed in **fast-twitch** fibers (**type II fibers**) within vertebrate **skeletal muscles**. These proteins are responsible for rapid contractions required during activities such as sprinting or sudden movements. Structurally, each molecule consists primarily of two heavy chains—encoded by genes such as *MYH1*, *MYH2*, *MYH4*—and four light chains. The head domain binds actin filaments and hydrolyzes ATP to generate mechanical force through conformational changes known as power strokes[5][7]. This process underlies the sliding filament mechanism central to all striated muscular contraction. Fast-type isoforms differ from their slow counterparts by exhibiting higher ATPase activity and faster crossbridge cycling rates, enabling quick but less fatigue-resistant contractions compared to slow-twitch fibers[4]. In addition to their primary role in movement generation, alterations or mutations affecting these molecules—or their regulatory partners like **fast skeletal myosin-binding protein-C** (*fMyBP-C*)—are implicated in various inherited muscular diseases including distal arthrogryposis and other forms of congenital weakness syndromes[1][3]. Therapeutic interest centers on modulating these proteins' function either directly through small molecules that affect contractility kinetics or indirectly via pathways regulating calcium sensitivity. However, achieving tissue-specific effects without impacting cardiac function remains an ongoing challenge due to structural similarities among different striated-muscle isoforms.

Other names
Fast myosinType II myosinSkeletal muscle type II myosin heavy chain (MyHC-II)Myh1, Myh2, Myh4 (gene/protein isoforms for human fast skeletal muscle)Fast-twitch myosin
02

Mechanism of action

For drugs targeting this molecule or its pathway— – Modulation of actin-myosin interaction kinetics to enhance force production or slow relaxation. – Alteration of calcium sensitivity within the contractile apparatus. – Stabilization or destabilization of crossbridge formation between actin and fast-type myosins.

03

Biological functions

Muscle contractionATP hydrolysis for energy transductionForce generation in fast-twitch (type II) skeletal musclesRegulation of actin-myosin crossbridge cycling
04

Disease associations

Muscular dystrophies and congenital myopathiesDistal arthrogryposis (via mutations in associated proteins like MYBPC2)Muscle weakness syndromesOther neuromuscular disorders
05

Safety considerations

Off-target effects on cardiac or slow-twitch muscles if specificity is not achieved.Risk of impaired fine motor control if modulation is excessive.Potential exacerbation of underlying neuromuscular pathology with inappropriate activation/inhibition.
06

Interacting drugs

There are currently no widely approved drugs that directly target fast skeletal muscle myosins specifically. However, some experimental agents modulate sarcomeric function or calcium sensitivity indirectly. Drugs targeting related pathways include:

1 more in the full profile.

07

Biomarkers

Expression levels of specific fast-type MyHC isoforms (e.g., MYH1, MYH2, MYH4) can serve as biomarkers for fiber type composition or disease states.Mutations in genes encoding associated proteins such as MYBPC2 may be used diagnostically for certain congenital conditions

Beyond the preview

Go deeper on Fast skeletal muscle myosin (None commonly used; sometimes abbreviated as "fast MyHC" (myosin heavy chain) in literature, but no universal abbreviation.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fast skeletal muscle myosin (None commonly used; sometimes abbreviated as "fast MyHC" (myosin heavy chain) in literature, but no universal abbreviation.).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call